Report library

Biomedtracker Q4 2020 Outlook Report

In this report, we cover catalysts from 35 drugs, devices, diagnostics, and deals expected to occur in Q4 2020. For each drug, the likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided. These data points were provided using a combination of Pharmapremia, Informa’s drug development benchmarking product utilizing Biomedtracker’s LOA data to assist in informed decisions about drug pipeline prioritization, partnerships, and acquisitions, and drug approval data from Biomedtracker.

October 9, 2020

Molecular Diagnostics Market

Molecular diagnostics is being applied to an increasingly wide range of applications in infectious disease, oncology, and genetic disease diagnosis and screening and to a number of emerging applications in other diseases. The global market for molecular diagnostics is expected to grow at a CAGR of 10.8% between 2019 and 2024, reaching a value of more than $12bn.

September 30, 2020

Multiple Myeloma KOL Interview – US

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for multiple myeloma. Drug adverse events and critical unmet needs are also discussed. Key therapies highlighted include Darzalex, Venclexta, Xpovio, Ygalo, Blenrep, and BCMA-targeted CAR-T therapies.

May 15, 2020

Multiple Myeloma KOL Interview – UK

This interview with a UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for multiple myeloma. Drug adverse events and UK market access issues are also discussed. Key therapies highlighted include Darzalex, Venclexta, Xpovio, Ygalo, Blenrep, and BCMA-targeted CAR-T therapies.

May 15, 2020

Market Spotlight: Lysosomal Storage Disorders

$1,318.00

This Market Spotlight report covers the Lysosomal Storage Disorders market, comprising epidemiology, key marketed and pipeline drugs, recent events and analyst opinion, key regulatory events, licensing and asset deals, probability of success, and clinical trials.

April 28, 2022

Non-Alcoholic Steatohepatitis (NASH) KOL Interview – US, Northeast

Key topics discussed in this specialist interview with a US-based key opinion leader (KOL) include the diagnostic landscape in NASH and future market trends, with a focus on GLP-1 agonists, FGF 19/21 analogs, and FXR agonists.

August 28, 2020

Disease Analysis: Respiratory Syncytial Virus (RSV) Prevention

Spinal Fusion: Implanted Instrumentation

Sales of implanted instrumentation for spinal fusion procedures totaled approximately $4.4bn in 2019, with sales expected to climb at a CAGR of 2.2% through 2024. Growth in the spinal fusion instrumentation market is being driven by several factors including the prevalence of degenerative disc disease, new surgical techniques and associated instrumentation that have expanded the range of product indications, and the launch of new enabling technology such as diagnostic, nerve monitoring, and navigation systems (including robotic-assisted surgery).

August 20, 2020

Drug Delivery: Infusion Devices – August 2020

This report provides a discussion of current/forecast markets, competitors, and opportunities in the global infusion drug delivery devices market, including the volumetric, syringe, ambulatory, disposable, implantable, and enteral pumps segments. Geographic regions covered include the US, five major European markets, Japan, and Rest of World markets; the forecast period is from 2019–24.

August 14, 2020

Neuromodulation: Spinal Cord Stimulation Devices Market

According to a recent CDC study, 20.1% of adults had chronic pain and 7.4% of adults had chronic pain that frequently limited life or work activities with similar numbers being reported in Europe. In 2021, the spinal cord stimulation (SCS) devices market was worth nearly $2.9 bn. Market drivers of the SCS devices market through 2026 will be driven by an aging population and an increase in selected conditions (eg back/leg pain, and a growing number of indications) that result in debilitating and unrelenting chronic pain.

February 22, 2022

Biomedtracker / Meddevicetracker Q3 2020 Outlook Report

In this report, we cover catalysts from 27 drugs, devices, diagnostics and deals expected to occur in Q3 2020. For each drug, the likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided.

July 1, 2020

Gastric Cancer KOL Interview – US

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for gastric cancer. Disease stratifications by staging and origin of the primary tumor, as well as unmet needs, are also discussed. Key therapies highlighted include Opdivo, Yervoy, Keytruda, Cyramza, Herceptin, and Enhertu.

August 5, 2020

Disease Analysis: Wet Age-Related Macular Degeneration

Market Spotlight: Ischemic Stroke

$1,318.00

This Market Spotlight report covers the Ischemic Stroke market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, licensing and asset acquisition deals and a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.

February 18, 2022